Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04007536 · ClinicalTrials.gov registry record
A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
A clinical trial, sponsored by Denali Therapeutics.
- Completed
- Registry status
- 18
- Enrollment target
NCT04007536: Completed study, sponsored by Denali Therapeutics.
NCT04007536 is a clinical trial that has completed, run by Denali Therapeutics. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04007536 has completed, sponsored by Denali Therapeutics.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
Study Summary
This is a six-part prospective, multicenter, multiregional observational study of patients with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, to assess biomarkers potentially related to disease severity and/or treatment response and prospectively assess the progression of disease in participants with MPS II who are aged ≤30 years at the time of enrollment.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-10-23 |
| Est. Completion | 2024-03-01 |
What the finished NCT04007536 record still lists
NCT04007536 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT04007536 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04007536 about?
NCT04007536 is a clinical study titled "A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome". This is a six-part prospective, multicenter, multiregional observational study of patients with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, to assess biomarkers potentially related to disease severity and/or treatment response and prospectively assess the progression of di...
What is the current status of trial NCT04007536?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2019-10-23. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT04007536?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04007536?
This trial is sponsored by Denali Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI